Charlotte Doublet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Charlotte Doublet has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Agata Cieslak
Universite Paris Cite, Institut Necker-Enfants Malades (INEM), Institut national de la sante et de la recherche medicale (Inserm) U1151
17 shared publications - Antoine Pinton
Institut Necker Enfants Malades, INSERM U1151, Centre National de la Recherche Scientifique Unité Mixte de Recherche 8253, Université Paris Cité, Paris, France
17 shared publications - Aurore Touzart
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany
17 shared publications - Aurélie Cabannes-Hamy
Hematology Centre Hospitalier de Versailles Site André Mignot Le Chesnay‐Rocquencourt France
17 shared publications - Charlotte Smith
Université Paris Cité, Institut Necker Enfants-Malades INEM, Institut National de la Santé et de la Recherche Médicale (Inserm) U1151, Paris, France
17 shared publications - Elizabeth Macintyre
University Paris Cité and Assistance Publique-Hôpitaux de Paris, AP-HP Centre, Paris, France
17 shared publications
Latest Publications
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Bivalent genes hypermethylated in PHF6 altered T-ALL and targeted by PHF6
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Bivalent genes hypermethylated in PHF6 altered T-ALL and targeted by PHF6
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Data from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Purpose:To assess the impact of PHF6 alterations on clinical outcome and therapeutical actionability in T-cell acute lymphoblastic leukemia (T-ALL).Experimental Design:We described PHF6 alterations in an adult cohort of T-ALL from the French trial Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)-2003/2005 and retrospectively analyzed clinical outcomes between PHF6-altered (PHF6ALT) and wild-type patients. We also used EPIC and chromatin immunoprecipitation sequencing data of patient samples to analyze the epigenetic landscape of PHF6ALT T-ALLs. We consecutively evaluated 5-azacitidine efficacy, alone or combined with venetoclax, in PHF6ALT T-ALL.Results:We show that PHF6 alterations account for 47% of cases in our cohort and demonstrate that PHF6ALT T-ALL presented significantly better clinical outcomes. Integrative analysis of DNA methylation and histone marks shows that PHF6ALT are characterized by DNA hypermethylation and H3K27me3 loss at promoters physiologically bivalent in thymocytes. Using patient-derived xenografts, we show that PHF6ALT T-ALL respond to the 5-azacytidine alone. Finally, synergism with the BCL2-inhibitor venetoclax was demonstrated in refractory/relapsing (R/R) PHF6ALT T-ALL using fresh samples. Importantly, we report three cases of R/R PHF6ALT patients who were successfully treated with this combination.Conclusions:Overall, our study supports the use of PHF6 alterations as a biomarker of sensitivity to 5-azacytidine and venetoclax combination in R/R T-ALL.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Purpose:To assess the impact of PHF6 alterations on clinical outcome and therapeutical actionability in T-cell acute lymphoblastic leukemia (T-ALL).Experimental Design:We described PHF6 alterations in an adult cohort of T-ALL from the French trial Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)-2003/2005 and retrospectively analyzed clinical outcomes between PHF6-altered (PHF6ALT) and wild-type patients. We also used EPIC and chromatin immunoprecipitation sequencing data of patient samples to analyze the epigenetic landscape of PHF6ALT T-ALLs. We consecutively evaluated 5-azacitidine efficacy, alone or combined with venetoclax, in PHF6ALT T-ALL.Results:We show that PHF6 alterations account for 47% of cases in our cohort and demonstrate that PHF6ALT T-ALL presented significantly better clinical outcomes. Integrative analysis of DNA methylation and histone marks shows that PHF6ALT are characterized by DNA hypermethylation and H3K27me3 loss at promoters physiologically bivalent in thymocytes. Using patient-derived xenografts, we show that PHF6ALT T-ALL respond to the 5-azacytidine alone. Finally, synergism with the BCL2-inhibitor venetoclax was demonstrated in refractory/relapsing (R/R) PHF6ALT T-ALL using fresh samples. Importantly, we report three cases of R/R PHF6ALT patients who were successfully treated with this combination.Conclusions:Overall, our study supports the use of PHF6 alterations as a biomarker of sensitivity to 5-azacytidine and venetoclax combination in R/R T-ALL.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Patient cohort used for in vitro drug sensitivity assay.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Patient cohort used for in vitro drug sensitivity assay.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Figure 2 (A) Bar graphs showing the significant association between PHF6 status and methylation clusters previously described by our team (1). (B) Kaplan-Meier curve of overall survival between PHF6ALT and PHF6WT patients within the cluster 5 (Top). Table depicting the number of individuals according to timepoints.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Figure 2 (A) Bar graphs showing the significant association between PHF6 status and methylation clusters previously described by our team (1). (B) Kaplan-Meier curve of overall survival between PHF6ALT and PHF6WT patients within the cluster 5 (Top). Table depicting the number of individuals according to timepoints.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Bivalent genes hypermethylated in PHF6 altered T-ALL and targeted by PHF6
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Bivalent genes hypermethylated in PHF6 altered T-ALL and targeted by PHF6
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Figure 1 (A) Circos plot representing mutations co-occurrences in PHF6WT (left) and PHF6ALT T-ALL (right). (B) Variant allele frequencies (VAF) of mutations at diagnosis and relapse. Genes are ordered by decreasing VAF at diagnosis from left to right.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Figure 1 (A) Circos plot representing mutations co-occurrences in PHF6WT (left) and PHF6ALT T-ALL (right). (B) Variant allele frequencies (VAF) of mutations at diagnosis and relapse. Genes are ordered by decreasing VAF at diagnosis from left to right.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Patient cohort used for in vitro drug sensitivity assay.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Patient cohort used for in vitro drug sensitivity assay.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
PHF6 variant allelic frequencies of the additional 37 non protocolar paired diagnosis/relapsed PHF6ALT patients.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
PHF6 variant allelic frequencies of the additional 37 non protocolar paired diagnosis/relapsed PHF6ALT patients.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Bivalent genes hypermethylated in PHF6 altered T-ALL and targeted by PHF6
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Bivalent genes hypermethylated in PHF6 altered T-ALL and targeted by PHF6
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Figure 1 (A) Circos plot representing mutations co-occurrences in PHF6WT (left) and PHF6ALT T-ALL (right). (B) Variant allele frequencies (VAF) of mutations at diagnosis and relapse. Genes are ordered by decreasing VAF at diagnosis from left to right.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Supplementary Figure 1 (A) Circos plot representing mutations co-occurrences in PHF6WT (left) and PHF6ALT T-ALL (right). (B) Variant allele frequencies (VAF) of mutations at diagnosis and relapse. Genes are ordered by decreasing VAF at diagnosis from left to right.